TAMPA, Fla. & DUBLIN--(BUSINESS WIRE)--Vycellix™, Inc., an immuno-discovery cell & gene therapy company, and Avectas Limited, a cell engineering technology business, today jointly announced that the ...
- Single-step CD45-engager technology shows robust immune evasion with functional persistence in pre-clinical models - Phase 1 study to evaluate ‘off-the-shelf’ natural killer cell cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback